120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
早期口腔鳞状细胞癌唾液外泌体纳米诊断新进展：平台、生物标志物和未来前景
Authors Zhao LX , Wang ET, Jia WH, Wang MH , Pan Z, Dong L, Wen HQ, Xu WH , Xu R
Received 28 October 2025
Accepted for publication 8 January 2026
Published 24 January 2026 Volume 2026:21 577306
DOI https://doi.org/10.2147/IJN.S577306
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Dong Wang
Lai-Xi Zhao,1,* En-Tang Wang,2,* Wen-Hao Jia,1 Mo-Han Wang,5 Zhao Pan,4 Liang Dong,4 Hui-Qin Wen,3 Wen-Hua Xu,1 Rui Xu1
1College & Hospital of Stomatology, Anhui Medical University, Anhui Province Key Laboratory of Oral Diseases Research, Hefei, 230032, People’s Republic of China; 2Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou, 310000, People’s Republic of China; 3Department of Blood Transfusion, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People’s Republic of China; 4Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, People’s Republic of China; 5Department of Oral and Maxillofacial Surgery, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Rui Xu, Email dentistxr@126.com Wen-Hua Xu, Email xuwenhua@ahmu.edu.cn
Abstract: Early oral squamous cell carcinoma (OSCC) is frequently missed because conventional imaging and biopsy are poorly suited to detect subtle, preclinical molecular changes. Emerging salivary exosome nanodiagnostics aims to convert an anatomically proximal, information-rich nanoscale biospecimen into quantitative and repeatable readouts for screening and longitudinal monitoring. Clinical translation, however, is constrained by four bottlenecks: (i) pre-analytical variability in saliva collection, processing, and storage; (ii) yield–purity trade-offs during vesicle enrichment; (iii) low-abundance tumor-derived signals masked by abundant background vesicles; and (iv) biomarker heterogeneity that limits robustness across cohorts. Here, we integrate the landscape of salivary exosomal biomarkers (nucleic acids, proteins, and other cargo) and synthesize nanotechnology-enabled solutions that directly address these barriers, including microfluidic and affinity-based enrichment, nucleic-acid amplification circuits (eg, RCA, HCR, CHA) for signal gain, and optical/electrochemical transduction (eg, SPR, SERS) compatible with microliter-scale samples. Beyond listing platforms, we propose a unifying framework: co-design capture and readout to preserve biological specificity, match biomarker modality to detection physics, and prioritize multi-marker panels with transparent analytical benchmarks. Finally, we outline a translational roadmap spanning standardization, reproducibility, prospective multicenter validation, manufacturability, and regulatory readiness to accelerate clinically actionable early OSCC detection.
Keywords: oral squamous cell carcinoma, salivary exosomes, exosomal biomarkers, liquid biopsy, nanodiagnostics, nanoplatform
1College & Hospital of Stomatology, Anhui Medical University, Anhui Province Key Laboratory of Oral Diseases Research, Hefei, 230032, People’s Republic of China; 2Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou, 310000, People’s Republic of China; 3Department of Blood Transfusion, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People’s Republic of China; 4Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, People’s Republic of China; 5Department of Oral and Maxillofacial Surgery, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Rui Xu, Email dentistxr@126.com Wen-Hua Xu, Email xuwenhua@ahmu.edu.cn
Abstract: Early oral squamous cell carcinoma (OSCC) is frequently missed because conventional imaging and biopsy are poorly suited to detect subtle, preclinical molecular changes. Emerging salivary exosome nanodiagnostics aims to convert an anatomically proximal, information-rich nanoscale biospecimen into quantitative and repeatable readouts for screening and longitudinal monitoring. Clinical translation, however, is constrained by four bottlenecks: (i) pre-analytical variability in saliva collection, processing, and storage; (ii) yield–purity trade-offs during vesicle enrichment; (iii) low-abundance tumor-derived signals masked by abundant background vesicles; and (iv) biomarker heterogeneity that limits robustness across cohorts. Here, we integrate the landscape of salivary exosomal biomarkers (nucleic acids, proteins, and other cargo) and synthesize nanotechnology-enabled solutions that directly address these barriers, including microfluidic and affinity-based enrichment, nucleic-acid amplification circuits (eg, RCA, HCR, CHA) for signal gain, and optical/electrochemical transduction (eg, SPR, SERS) compatible with microliter-scale samples. Beyond listing platforms, we propose a unifying framework: co-design capture and readout to preserve biological specificity, match biomarker modality to detection physics, and prioritize multi-marker panels with transparent analytical benchmarks. Finally, we outline a translational roadmap spanning standardization, reproducibility, prospective multicenter validation, manufacturability, and regulatory readiness to accelerate clinically actionable early OSCC detection.
Keywords: oral squamous cell carcinoma, salivary exosomes, exosomal biomarkers, liquid biopsy, nanodiagnostics, nanoplatform